RAPS Virtual Program to cover advertising, promo and labeling for drugs and devices

RAPS Virtual Program on Advertising, Promotion and Labeling for Drugs and Devices to Cover FTC and FDA Enforcement, Social Media, Sunshine Act and More

This content was submitted directly to this website by the supplier.

The Regulatory Affairs Professionals Society (RAPS) will host a virtual workshop, Advertising, Promotion and Labeling: the US Regulated Environment, Monday, 29 April, 12:00–5:00 pm EDT. The program features regulators and regulatory experts on current communications guidelines and expectations for companies marketing regulated healthcare products in the US.

Among the program’s speakers is Richard L. Cleland, assistant director, Division of Advertising Practices, for the Federal Trade Commission (FTC), who will present a case study examining ad interpretation and scientific substantiation for regulated products, and an analysis of recent legal rulings.

The workshop also will cover false claims enforcement activities by both FTC and the US Food and Drug Administration (FDA); direct-to-consumer marketing; the use of social media to discuss biologics, drugs and medical devices; regulatory’s role in managing intended use and off-label promotion; and a look at how the new Sunshine Act affects promotional activities.

Other expert speakers on the agenda include Carol Cooper, MS, RAC, associate director of regulatory affairs in regulatory operations and compliance at Baxter Healthcare; Stefanie Doebler, JD, MPH, MA, special counsel in Covington & Burling LLP; and Bradley Merrill Thompson, JD, MBA, RAC, attorney, Epstein Becker & Green PC, and strategic counsel with EBG Advisors Inc.

Advance registration is open through 24 April. Interested members of the media should contact RAPS Senior Manager of Communications Zachary Brousseau at zbrousseau@raps.org or +1 301 770 2920, ext. 245.

More in Home